If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Compared with endocrine therapy, radiotherapy was associated with a smaller reduction in health-related quality-of-life in ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

Postmenopausal women with vulvovaginal atrophy treated with intravaginal prasterone for at least 12 weeks were nearly 50% ...

Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Patrick Payne, a Group 1-winning trainer, has been charged by Racing Victoria (RV) stewards after presenting a horse to the ...

Trainer to face charges for presenting horse to the races twice in 2024 with several banned substances in his system ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings ...